Sangamo Q3 net loss $34.9M, revenue $0.6M; advancing Fabry BLA and pain trial enrollment

SANGAMO THERAPEUTICS, INC

2025-Q3 EPS reported -$0.33 revenue$25,324,000

Q3 2025 consolidated net loss $34.9M ($0.11/sh) vs net income $10.7M ($0.04/sh) in prior year.
Revenue of $0.6M down from $49.4M, mainly due to absence of Genentech collaboration revenue.
Cash and equivalents $29.6M; with Pfizer $6M license fee and ATM proceeds, runway into Q1 2026.
FDA reiterated eGFR slope endpoint for isaralgagene civaparvovec accelerated approval; BLA submission expected as early as Q1 2026.
First two clinical sites activated for Phase 1/2 ST-503 chronic neuropathic pain study; first patient dosing expected in coming months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.